Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTM2 | P28161 | 10/20 | 0.56 |
| ▸ | GSTP1 | P09211 | 9/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 5/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | G6PD | P11413 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.50 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.50 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7052057 | 0.85 | GSTM2 (0.66) | GSTM2GSTP1MEN1KMT2AIDO1 | |
| SCHEMBL8788825 | 0.85 | GSTM2 (0.51) | GSTM2GSTP1MEN1KMT2AIDO1 | |
| SCHEMBL25868523 | 0.84 | GSTM2 (0.51) | GSTM2GSTP1MEN1KMT2ANPC1 | |
| SCHEMBL2608494 | 0.80 | GSTP1 (0.61) | GSTM2GSTP1MEN1KMT2AIDO1 | |
| SCHEMBL3501548 | 0.80 | MEN1 (0.60) | GSTM2GSTP1MEN1KMT2ANPC1 | |
| SCHEMBL28945749 | 0.78 | GSTM2 (0.46) | GSTM2GSTP1MEN1KMT2ANPC1 | |
| SCHEMBL3500091 | 0.78 | MEN1 (0.60) | GSTM2GSTP1MEN1KMT2ANPC1 | |
| SCHEMBL1076589 | 0.78 | MEN1 (0.60) | GSTM2GSTP1MEN1KMT2ANPC1 | |
| SCHEMBL17781757 | 0.78 | MEN1 (0.67) | GSTM2GSTP1MEN1KMT2ANPC1 | |
| SCHEMBL17914175 | 0.76 | MEN1 (0.63) | GSTM2GSTP1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067952-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| US-11858917-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | YALE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| US-11725064-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2023-08-15 | — | — | US | disclosed |
| US-10030008-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2018-07-24 | — | — | US | disclosed |
| US-10016412-B2 | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) | YALE UNIVERSITY (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180155332-A1 | SMALL MOLECULE BASED ANTIBODY-RECRUITING COMPOUNDS FOR CANCER TREATMENT | YALE UNIVERSITY | 2018-06-07 | — | — | US | disclosed |
| US-20170096415-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | UNIV YALE (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170087148-A1 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMs) | UNIV YALE (US) | 2017-03-30 | — | — | US | disclosed |
| US-9181224-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150110742-A1 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMS) | YALE UNIVERSITY (US) | 2015-04-23 | — | — | US | disclosed |
| US-20140308342-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-16 | — | — | US | disclosed |
| US-8859509-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2014-10-14 | — | — | US | disclosed |
| US-8852630-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130245040-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-19 | — | — | US | disclosed |
| US-20120269766-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIVERSITY (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120034295-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | YALE UNIVERSITY | 2012-02-09 | — | — | US | disclosed |
| US-20110201563-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | YALE UNIVERSITY (US) | 2011-08-18 | — | — | US | disclosed |
| US-20080262254-A1 | Sphingolipids | ETTMAYER PETER | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140308342-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | PLAUR, CD47, CD14 | GSTM2 1267/4885GSTP1 2170/4885MEN1 2894/4885 |
| US-11767301-B2 | Bi-functional molecules to degrade circulating proteins | MIF, ASGR1, FCGR2A | GSTM2 163/4885GSTP1 207/4885MEN1 1417/4885 |
| US-11725064-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | BRDT, PAICS, KLK3 | GSTM2 453/4885GSTP1 502/4885MEN1 1313/4885 |
| US-10016412-B2 | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) | TLR3, TLR4, TLR1 | GSTM2 1175/4885GSTP1 970/4885MEN1 3416/4885 |
| US-20120034295-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | GSTM2 453/4885GSTP1 502/4885MEN1 1313/4885 |
| US-20180155332-A1 | SMALL MOLECULE BASED ANTIBODY-RECRUITING COMPOUNDS FOR CANCER TREATMENT | PLAUR, C5AR1, C3AR1 | GSTM2 2446/4885GSTP1 2941/4885MEN1 1364/4885 |
| US-20170087148-A1 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMs) | TLR3, TLR4, TLR1 | GSTM2 1175/4885GSTP1 970/4885MEN1 3416/4885 |
| US-20150110742-A1 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMS) | TLR3, TLR4, TLR1 | GSTM2 1175/4885GSTP1 970/4885MEN1 3416/4885 |
| US-20080262254-A1 | Sphingolipids | SGMS2, SGMS1, SGPL1 | GSTM2 2272/4885GSTP1 2292/4885MEN1 376/4885 |
| US-20240067952-A1 | REPROGRAMMING UROKINASE INTO AN ANTIBODY-RECRUITING ANTICANCER AGENT | PLAUR, CD47, CD14 | GSTM2 1267/4885GSTP1 2170/4885MEN1 2894/4885 |
| US-10030008-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | CD4, HAVCR2, CD2 | GSTM2 537/4885GSTP1 1085/4885MEN1 3370/4885 |
| US-11858917-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | CD4, HAVCR2, CD2 | GSTM2 537/4885GSTP1 1085/4885MEN1 3370/4885 |
| US-20120269766-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2BP2 | GSTM2 435/4885GSTP1 1101/4885MEN1 3119/4885 |
| US-20170096415-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2 | GSTM2 537/4885GSTP1 1085/4885MEN1 3370/4885 |
| US-20110201563-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | GSTM2 453/4885GSTP1 502/4885MEN1 1313/4885 |
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | GSTM2 453/4885GSTP1 502/4885MEN1 1313/4885 |
| US-20130245040-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2 | GSTM2 537/4885GSTP1 1085/4885MEN1 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.